Listed

NEUROONE MEDICAL TECHNOLOGIES Corp: Form 10-Q for the period ended Dec 31, 2018

Filed with the SEC on Feb 14, 2019 and accepted by EDGAR at Feb 14, 2019, 21:09 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2018-10-01 to 2018-12-31$209.2kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-10-01 to 2018-12-31−$1.1mus-gaap:OperatingIncomeLoss
Net income3 months2018-10-01 to 2018-12-31−$1.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-10-01 to 2018-12-31−$0.14us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2018-10-01 to 2018-12-31−$699.7kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2018-12-31$350.6kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-12-31$382.8kus-gaap:AssetsCurrent
Total assetsAt period end2018-12-31$577.5kus-gaap:Assets
Current liabilitiesAt period end2018-12-31$4.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-12-31$5.5mus-gaap:Liabilities
Shareholders' equityAt period end2018-12-31−$5.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-19-002554. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.